Bachem Holding stock
Price history
+54.13% over the period1 year: from CHF 49.44 (November 20, 2025) to CHF 76.20 (November 20, 2026), +54.13%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | CHF 76.20 |
| October 30, 2026 | CHF 84.05 |
| September 30, 2026 | CHF 81.05 |
| August 31, 2026 | CHF 75.60 |
| July 31, 2026 | CHF 74.80 |
| June 30, 2026 | CHF 75.65 |
| May 29, 2026 | CHF 76.85 |
| April 30, 2026 | CHF 70.80 |
| March 31, 2026 | CHF 64.85 |
| February 27, 2026 | CHF 59.40 |
| January 30, 2026 | CHF 70.00 |
| December 30, 2025 | CHF 59.90 |
| November 28, 2025 | CHF 51.85 |
| November 20, 2025 | CHF 49.44 |
At a glance
The company
Develop and produce peptide and oligonucleotide active pharmaceutical ingredients for pharmaceutical and biotechnology companies
Latest results
Quarter to June 30, 2026 · EPS CHF 0.67
Next event
TickerLandia's take on Bachem Holding
- Priced as usual relative to earnings: P/E on the latest fiscal year 38 vs a median of 41 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 39 vs 39 (+0%) in a group of 9.
- Strong point: Earnings stability (90/100 in its group). Weak point: Growth (32/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−11.40% from the 52-week high
Analysts · 10 analysts
Average targetCHF 84.30+10.63% vs. price
Buy 6 · Hold 3 · Sell 1 · Buy
TickerLandia Fingerprint: Bachem Holding
Compared with similar companies: very high earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage47
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 38.7 55 EV/EBITDA 29.2 61 Price/book 3.98 28 Price/sales 8.11 46 Forward P/E 24.9 44 Profitabilityaverage45
How much it earns on revenue and capital.
Metric Value Position in group Net margin 21.0% 61 ROE 10.6% 48 ROA 4.5% 45 Gross margin 27.0% 9 Operating margin 21.8% 60 Earnings stabilityvery high90
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.5% 96 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthlow32
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) 0.00% 51 Revenue growth (year over year) +4.30% 22 Average revenue growth (3 years) +9.34% 24 Financial strengthaverage49
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.60 11 Debt/equitycounts in reverse: lower means more financial strength 0.14 46 Interest coverage 420.4 92 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.13 46 Dividendhigh70
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.2% 53 Consecutive dividend years at least 28 years 93 Payout ratio 45.5% 64 Market momentumaverage58
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −2.93% 40 Relative strength (6 months) −10.69% 34 1-year return +54.13% 92 Distance from 200-day average +4.39% 65 Riskaverage55
How much the price swings.
Metric Value Position in group Beta (1 year) 0.79 53 Volatility (60 days) 28.2% 53 Maximum drawdown (12 months) 27.0% 59
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Bachem Holding is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Bachem Holding's P/E today is 38.4, in line with the median of its last 10 fiscal years (41.5; between 29.7 and 88.5 from 2016 to 2025). Bachem Holding's P/E (trailing 12 months): 38.7, in line with the median of a group of 9 similar companies (38.7).
Compared with 9 similar companies
| Metric | Bachem Holding | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 38.7 | Middle | |
| Forward P/E | 24.9 | Low | |
| Operating margin | 21.8% | Middle | |
| ROE | 10.6% | Middle | |
| Debt/equity | 0.14 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bachem Holding. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
CHF 326.45M
Latest quarter · Q2 2026
Net income
CHF 50.27M
Latest quarter · Q2 2026
Quarterly net margin
15.4%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- CHF 5.74B
- P/E
- 38.7
- EPS
- CHF 1.98
- Volume
- 58.82K
- Daily trading
- €6.58M
- Dividend yield
- 1.18%
- Last ex-dividend on May 4, 2026
How Bachem Holding is changing
All resultsRevenue grew 11.6% a year on average over the last 5 years
Less cash than profit: free cash flow equal to -50% of net income
Shares outstanding up 7.1% in 5 years
Returns
Bachem Holding returns with dividends
CHF 1,000 invested in Bachem Holding 5 years ago, on November 22, 2021, would be worth CHF 588 today with dividends reinvested: −41.18% in total, −10.08% per year. On price alone it would be CHF 557 (−44.30%).
| Period | Bachem Holding | SMI | CHF 1,000 becomes |
|---|---|---|---|
| 1 month | −11.40% | +0.65% | CHF 886 |
| 6 months | −2.87% | +8.75% | CHF 971 |
| Year to date | +27.21% | +9.83% | CHF 1,272 |
| 1 year | +56.00% | +16.18% | CHF 1,560 |
| 3 years | +11.63% | +35.68% | CHF 1,116 |
| 5 years | −41.18% | +16.48% | CHF 588 |
| 10 years | +408.40% | +85.64% | CHF 5,084 |
Over the last 6 months it has done better than 11% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment
The chart in detail
Bachem Holding: technical analysis
Bachem Holding shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 54.5% below its all-time closing high (CHF 167.60, October 15, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 36
- Between 30 and 70
- vs 200-session average
- +4.39%
Active signals
Close below the low of the previous 20 sessions.
Trading on November 20, 2026 was 2.4 times the 20-session average.
Support and resistance
Price areas where Bachem Holding has stopped several times in the last year. They describe the chart; they are not forecasts.
- ResistanceCHF 83.15+9.12%6 touches, last on October 6, 2026
- ResistanceCHF 79.98+4.96%5 touches, last on October 23, 2026
- ResistanceCHF 77.60+1.84%2 touches, last on November 6, 2026
- Last priceCHF 76.20
- SupportCHF 74.44−2.31%4 touches, last on September 17, 2026
- SupportCHF 69.10−9.32%2 touches, last on July 30, 2026
- SupportCHF 66.96−12.12%4 touches, last on April 24, 2026
Volatility and risk
Over the last year it has moved less than the SMI.
- Beta (1 year) vs SMI
- 0.79
- Volatility (60 sessions, annualised)
- 28.2%
- Largest fall in the last year
- −26.97%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Bachem Holding: seasonality
Average monthly price change over 29 years
Over the last 29 years, the strongest month for Bachem Holding has been March: +5.10% on average, positive in 19 years out of 28. The weakest has been September: −2.19% on average, positive in 9 years out of 29. November, the current month, has been positive in 8 years out of 28 (−1.99% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −0.46% | +0.64% | 17 of 28 |
| February | −0.18% | −1.18% | 11 of 28 |
| March | +5.10% | +5.05% | 19 of 28 |
| April | +2.70% | +1.15% | 18 of 28 |
| May | +0.70% | −0.19% | 13 of 28 |
| June | −1.41% | −0.88% | 12 of 28 |
| July | +1.09% | −0.52% | 13 of 28 |
| August | +1.44% | +0.78% | 15 of 29 |
| September | −2.19% | −0.70% | 9 of 29 |
| October | +2.00% | +0.57% | 15 of 29 |
| November | −1.99% | −2.86% | 8 of 28 |
| December | +2.88% | +3.12% | 19 of 28 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Bachem Holding and its competitors
Pharmaceutical and biotech companies around the world rely on Bachem Holding AG, which develops and manufactures peptide active pharmaceutical ingredients. Its portfolio spans peptide and oligonucleotide new chemical entities, commercial new chemical entities and generics. Alongside production, the group provides project management, analytical services, quality and regulatory work, research-grade production and supply services.
- Headquarters
- Bubendorf, Switzerland
- Employees
- 2,725
- Founded
- 1971
- Chief executive
- Anne-Kathrin Stoller
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Bachem HoldingBANB | $6.84B | 21.8% | 38.7 | −2.87% |
| ABIVAXABVX | $6.06B | -6,270.4% | — | −38.78% |
| ALK-AbellóALK.B | $7.79B | 26.6% | 38.0 | −7.14% |
| CamurusCAMX | $4.32B | 37.4% | 58.7 | +37.97% |
| Financière de TubizeTUB | $11.25B | 0.0% | 104.1 | +9.99% |
| Bavarian NordicBAVA | $2.72B | 18.1% | 12.7 | +24.00% |
Same industry or related industries, similar size. Compare Bachem Holding with its competitors · Full profile
